# TRXB catalysts: TRex Bio, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/trxb/catalysts

> TRex Bio, Inc. (TRXB) has 3 upcoming catalysts. The next is the TRB-071 trial start, 1H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for TRXB?

TRex Bio, Inc. (TRXB) has 3 upcoming catalysts. The next is the TRB-071 trial start, 1H 2027. SEC prospectus (424B): "We are currently conducting a three-month Good Laboratory Practice ("GLP") toxicology study of TRB-071 in cynomolgus monkeys and, subject to regulatory allowance to proceed, expect to initiate a Phase 1 clinical trial in the first half of 2027." [Calendar and source filings](https://sec-api.dev/companies/trxb/catalysts)

Source: SEC prospectus (424B), accession 0001193125-26-419203, https://www.sec.gov/Archives/edgar/data/2139097/000119312526419203/project_dino_-_424b4.htm (retrieved 2026-11-12). Last confirmed 2026-11-13. Cite: https://sec-api.dev/companies/trxb/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | TRex Bio, Inc. |
| Ticker | TRXB (Nasdaq) |
| SEC CIK | 2139097 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/trxb |

## Cash runway

Cash $78.2M as of 2026-09-30; quarterly burn $12.6M; about 18.6 months of runway at that rate (XBRL company facts, accession 0001193125-26-460786).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jun 2024 | [TRB-051 trial start](https://sec-api.dev/pdufa/trb-051) | TRXB |  | completed | "In June 2024, we announced that Lilly initiated a Phase 1 first-in-human study for TRB-051." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/2139097/000119312526460786/ck0002139097-20260930.htm)) |
| Aug 2026 | [TRB-061 topline data readout](https://sec-api.dev/pdufa/trb-061) | TRXB |  | completed, positive | "Reported positive Phase 1a topline results supporting proof of mechanism: In August 2026, TRexBio announced positive topline results from the Phase 1a portion of its ongoing Phase 1a/b clinical trial of TRB-061 in healthy volunteers." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2139097/000119312526460588/ck0002139097-ex99_1.htm)) |
| November 13, 2026 | [TRex Bio, Inc. earnings report](https://sec-api.dev/companies/trxb/catalysts) | TRXB |  | completed | "TRexBio Reports Third Quarter 2026 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2139097/000119312526460588/ck0002139097-ex99_1.htm)) |
| 1H 2027 | [TRB-071 trial start](https://sec-api.dev/pdufa/trb-071) | TRXB |  | scheduled | "We are currently conducting a three-month Good Laboratory Practice ("GLP") toxicology study of TRB-071 in cynomolgus monkeys and, subject to regulatory allowance to proceed, expect to initiate a Phase 1 clinical trial in the first half of 2027." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/2139097/000119312526419203/project_dino_-_424b4.htm)) |
| mid-2027 | [TRB-061 topline data readout](https://sec-api.dev/pdufa/trb-061) | TRXB | moderate-to-severe AD began in April 2026 | scheduled | "Topline data are expected in mid-2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2139097/000119312526460588/ck0002139097-ex99_1.htm)) |
| 2H 2027 | [TRB-061 trial start](https://sec-api.dev/pdufa/trb-061) | TRXB | moderate-to-severe AD | scheduled | "Assuming supporting results and subject to regulatory submission and feedback, we expect to commence a Phase 2 clinical trial of TRB-061 in adult patients with moderate-to-severe AD at multiple sites in the United States and globally in the second half of 2027." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/2139097/000119312526419203/project_dino_-_424b4.htm)) |

## Drugs

- [TRB-051](https://sec-api.dev/pdufa/trb-051): 
- [TRB-061](https://sec-api.dev/pdufa/trb-061): moderate-to-severe ad in mid-2027, moderate-to-severe ad, moderate-to-severe ad began in april 2026
- [TRB-071](https://sec-api.dev/pdufa/trb-071): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/trxb/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TRXB catalysts: TRex Bio, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/trxb/catalysts

```bibtex
@misc{secapidev_companies_trxb_catalysts_20261116,
  title        = {TRXB catalysts: TRex Bio, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/trxb/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_trxb_catalysts_20261116","title":"TRXB catalysts: TRex Bio, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/trxb/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
